ONCOLOGY Vol 39, Issue 6

home / journals / oncology / oncology-vol-39-issue-6

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

3 Things You Should Know About Managing Advanced Melanoma With Oncolytic Viral Immunotherapies

July 30th 2025

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.

3 Things You Should Know About Evolving Strategies in SCLC: Limited-Stage Advances, Frontline Innovation, and Postplatinum Progress

ONCOLOGY Staff

July 29th 2025

ArticlePerspective

Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.

Explore the latest advancements in sarcoma immunotherapy, focusing on tumor microenvironment modulation and innovative treatment strategies for improved patient outcomes.

Immune Modulation in Sarcoma: Targeting the Tumor Microenvironment

Viviana Cortiana, MS4;Jenna Ghazal, BSc;Harshitha Vallabhaneni, BS;Ahmed Hashim Azeez, MD;Kennedy Itodo, BS;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD

July 28th 2025

ArticleReview Article

Explore the latest advancements in sarcoma immunotherapy, focusing on tumor microenvironment modulation and innovative treatment strategies for improved patient outcomes.

The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.

Top Trials From the 2025 ASCO and EHA Meetings

Julie M. Vose, MD, MBA

July 25th 2025

ArticlePerspective

The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.

Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.

Taletrectinib Increases Already Broad Selection of ROS1+ NSCLC Therapies

Tim Cortese

June 25th 2025

ArticleInterview

Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.